Effect of Wuye Decoction on lymphocyte phenotype in patients with non-small cell lung cancer

Zheng Shun-li; Yang Qing-sheng; Ma Xiao-hong

doi:10.1007/BF02857357

Your Location：

Home >

Browse articles >

Effect of Wuye Decoction on lymphocyte phenotype in patients with non-small cell lung cancer

Updated：2021-08-27

- Effect of Wuye Decoction on lymphocyte phenotype in patients with non-small cell lung cancer
- Chinese Journal of Integrative Medicine Vol. 12, Issue 2, Pages: 118-121(2006)
- Affiliations：
  
  Department of Cardiothoracic Surgery, the First Affiliated Hospital of Jinan University,Guangzhou
- Author bio：
- Funds：
- DOI：10.1007/BF02857357
  CLC：
- Published：2006，
Scan for full text
Shun-li, Z., Qing-sheng, Y. & Xiao-hong, M. Effect of Wuye Decoction on lymphocyte phenotype in patients with non-small cell lung cancer., Chin. J. Integr. Med. 12, 118–121 (2006). https://doi.org/10.1007/BF02857357

Zheng Shun-li, Yang Qing-sheng, Ma Xiao-hong. Effect of Wuye Decoction on lymphocyte phenotype in patients with non-small cell lung cancer. [J]. Chinese Journal of Integrative Medicine 12(2):118-121(2006)
Shun-li, Z., Qing-sheng, Y. & Xiao-hong, M. Effect of Wuye Decoction on lymphocyte phenotype in patients with non-small cell lung cancer., Chin. J. Integr. Med. 12, 118–121 (2006). https://doi.org/10.1007/BF02857357 DOI：

Zheng Shun-li, Yang Qing-sheng, Ma Xiao-hong. Effect of Wuye Decoction on lymphocyte phenotype in patients with non-small cell lung cancer. [J]. Chinese Journal of Integrative Medicine 12(2):118-121(2006) DOI： 10.1007/BF02857357.

摘要

Objective: To investigate the effect of Chinese recipe

Wuye Decoction (WYD)

on immune function in patients with non-small cell lung cancer (NSCLC).Methods: Eighty-two patients of NSCLC with pathologically confirmed diagnosis

who had received operative treatment and completed the post-operational chemotherapy

were randomly assigned into 2 groups. Group A (42 cases) received WYD and Group B (40 cases) received no specific medicine. Positive rate of various peripheral lymphocyte subsets

including CD3

CD4

CD8

CD16

CD19 and CD25

in both groups was observed immediately after chemotherapy (T0) and 3 months later (T1)

the same indexes of 20 healthy volunteers allocated in Group C were also determined at T0 for control.Results: The positive rates of CD4

CD4/CD8

CD16

CD19 and CD25 were significantly lower (P< 0.05) while that of CD8 was significantly higher (P< 0. 05) in Group A and B at T0 than those in Group C; at T1

these indexes

except CD25

got significantly restored in Group A with the level approaching normal range (P> 0.05)

and showed significant difference from those in Group B (P< 0. 05)

since these indexes in that group remained unchanged at the corresponding period. As for CD25

it was insignificantly changed in Group A after WYD treatment

and thus

at T1

it was still lower than that in Group C (P< 0.05) and showed insignificant difference as compared with that in Group B (P>0.05). Comparison of CD3 among the 3 groups showed no significant difference (P> 0.05).Conclusion: WYD could activate the immune function of NSCLC patients

and so it is recommended to be used in the treatment of NSCLC in clinical practice.

Abstract

Objective: To investigate the effect of Chinese recipe

Wuye Decoction (WYD)

on immune function in patients with non-small cell lung cancer (NSCLC).Methods: Eighty-two patients of NSCLC with pathologically confirmed diagnosis

who had received operative treatment and completed the post-operational chemotherapy

were randomly assigned into 2 groups. Group A (42 cases) received WYD and Group B (40 cases) received no specific medicine. Positive rate of various peripheral lymphocyte subsets

including CD3

CD4

CD8

CD16

CD19 and CD25

in both groups was observed immediately after chemotherapy (T0) and 3 months later (T1)

the same indexes of 20 healthy volunteers allocated in Group C were also determined at T0 for control.Results: The positive rates of CD4

CD4/CD8

CD16

CD19 and CD25 were significantly lower (P< 0.05) while that of CD8 was significantly higher (P< 0. 05) in Group A and B at T0 than those in Group C; at T1

these indexes

except CD25

got significantly restored in Group A with the level approaching normal range (P> 0.05)

and showed significant difference from those in Group B (P< 0. 05)

since these indexes in that group remained unchanged at the corresponding period. As for CD25

it was insignificantly changed in Group A after WYD treatment

and thus

at T1

and so it is recommended to be used in the treatment of NSCLC in clinical practice.

关键词

Wuye Decoctionnon-small cell lung cancerchemotherapylymphocyte phenotype

Keywords

Wuye Decoctionnon-small cell lung cancerchemotherapylymphocyte phenotype

references

Shu XH, Yang SR. Clinical efficacy of Aidi injection combined with chemotherapy in treating moderate late non small cell lung cancer. Sichuan J Cancer Control 2005; 18 (2): 95–97.

Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111(6): 1710–1717.

Jiangsu New Medical College. Dictionary of materia medica. Vol 1. Shanghai: Shanghai Scientific and Technical Publishers, 1986: 555–558.

Hatakeyama N, Tamura Y, Sahara H, et al. Induction of autologus CD4 and CD8 mediated T-cell responses against acute lymphocytic leukemia cell line using apoptotic tumor cell loaded dendritic cells. Exp Hematol 2006; 34 (2): 197–207.

Schleypen JS, Baur N, Kammerer R, et al. Cytotoxic markers and frequency predict functional of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res 2006; 12(3): 718–725.

Ishigami S, Natsugoe S, Tokuda K, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000; 88(3): 577–583.

Yao FX, Zheng H, Li HY, et al. Effect of chemotherapy on cellular immune function in lung cancer patients. Chin Tumor Clin Rehabil 2001; 8 (2): 53–54.

FULL TEXT LINK

More>

Views

334

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

In Vitro and In Vivo inhibitory effect of the combination of Wenxia Changfu Formula (温下肠腑方) with cisplatin in non-small cell lung cancer

Shenyi Capsule (参一胶囊) plus Chemotherapy versus Chemotherapy for Non-Small Cell Lung Cancer: A Systematic Review of Overlapping Meta-Analyses

Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and western medicine

Application of Response Evaluation Criteria of Traditional Chinese Medicine for Solid Tumor in advanced non-small cell lung cancer

The treatment of non-small cell lung cancer by interstitial I-125 seeds implantation combined with chemotherapy and Chinese medicine

Related Author

No data

Related Institution

School of Basic Medical Science, Shandong University of Traditional Chinese Medicine

Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences

Department of Oncology, The East Campus of Dongzhimen Hospital, Beijing University of Chinese Medicine

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute

Department of Oncology, First Affiliated Hospital of Guangzhou University of Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰